This presentation provides an overview of NeoGenomics, a cancer genetics testing company. Key points include:
- NeoGenomics has experienced strong and consistent growth in revenue and test volume historically through strategic partnerships and an expanding test menu.
- The company focuses on fast turnaround times and exceptional client service to drive continued growth.
- Management aims to increase market share and profitability through expanding sales coverage, new test offerings like next generation sequencing, and potential M&A opportunities.
- NeoGenomics seeks to capitalize on favorable industry trends like an aging population, rise of personalized medicine, and consolidation in the cancer diagnostics field.
In this NeoGenomics Laboratory Company Overview Presentation 02/19/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
March 2017 Company Overview Presentation by NeoGenomics, (Nasdaq: NEO) a fast...Hawk Associates, Inc.
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory and pharma services company that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics. Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US. NeoGenomics services the needs of pathologists, oncologists, urologists and other physician specialists, academic institutions, and the pharmaceutical industry.
The company’s acquisition of Clarient at the end of 2015 significantly transformed the company in terms of reach and capabilities. It more than doubled the size of the company overnight and puts the company on a strong path to achieve its vision of becoming the world’s leading cancer testing and information company.
The company has aggressively accelerated its pace of innovation adding new cancer tests. The company’s targeted tumor-specific multimodality NeoTYPE profiles, which combine molecular, FISH and IHC testing, are gaining acceptance by pathologists and clinicians. The new Liquid Biopsy NeoLAB family of tests now includes 16 different liquid biopsy test. Clarient’s expertise in PDL1 testing has further broadened the company’s cancer testing menu.
In this NeoGenomics Laboratory Company Overview Presentation 01/09/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
NeoGenomics Forward-looking statements, Investment Highlights, Consistent Historical Growth, Accelerating Cash FLow & Earnings, Management Team, Cancer Testing Services, Customer Targets, NeoGenomics Formula for Success, Industry Dynamics, US Cancer Testing Market Size, Cancer Testing Market Characteristics, Key Growth Drivers Over the Next 3 Years...
In this NeoGenomics Laboratory Company Overview Presentation 02/19/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
March 2017 Company Overview Presentation by NeoGenomics, (Nasdaq: NEO) a fast...Hawk Associates, Inc.
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory and pharma services company that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics. Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US. NeoGenomics services the needs of pathologists, oncologists, urologists and other physician specialists, academic institutions, and the pharmaceutical industry.
The company’s acquisition of Clarient at the end of 2015 significantly transformed the company in terms of reach and capabilities. It more than doubled the size of the company overnight and puts the company on a strong path to achieve its vision of becoming the world’s leading cancer testing and information company.
The company has aggressively accelerated its pace of innovation adding new cancer tests. The company’s targeted tumor-specific multimodality NeoTYPE profiles, which combine molecular, FISH and IHC testing, are gaining acceptance by pathologists and clinicians. The new Liquid Biopsy NeoLAB family of tests now includes 16 different liquid biopsy test. Clarient’s expertise in PDL1 testing has further broadened the company’s cancer testing menu.
In this NeoGenomics Laboratory Company Overview Presentation 01/09/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
NeoGenomics Forward-looking statements, Investment Highlights, Consistent Historical Growth, Accelerating Cash FLow & Earnings, Management Team, Cancer Testing Services, Customer Targets, NeoGenomics Formula for Success, Industry Dynamics, US Cancer Testing Market Size, Cancer Testing Market Characteristics, Key Growth Drivers Over the Next 3 Years...
In this NeoGenomics Laboratory Company Overview Presentation 01/09/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
NeoGenomics Company Overview highlights. It includes investment highlights, Consistent historical growth charts, accelerating cash flow & earnings, management team, testing services, customer targets, formula for success, industry dynamics, U.S. cancer market size, cancer testing market characteristics, key growth drivers...
This presentation contains statements which constitute forward-looking statements within the meaning of Section 27A of the Securities Act, as amended; Section 21E of the Securities Exchange Act of 1934; and the Private Securities Litigation Reform Act of 1995. The words “may”, “would”, “could”, “will”, “expect”, “estimate”, “anticipate”, “believe”, “intend”, “plan”, “goal”, and similar expressions and variations thereof are intended to specifically identify forward-looking statements. All statements that are not statements of historical fact are forward-looking statements.
Investors and prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. The risks that might cause such differences are identified in our filings with the Securities and Exchange Commission. We undertake no obligation to publicly update or revise the forward looking statements made in this presentation to reflect events or circumstances after
NeoGenomics Company Overview 2014-09-12 includes the following sections:
-Forward-looking Statements
-Investment Highlights
-Experienced Management Team
-Company Overview
-Proven Track Record Of Consistent Growth
-U.S. Cancer Testing Market Size $10-12 Billion
-NeoGenomics' Cancer Testing Services
-Customer Targets
-Accelerating Pace of Innovation
-90+ New Assays Launched Since January 2012
-A Growing Commercial & Facility Footprint
-Acquisition of Path Logic
-Strategic Alliance
-2014 and 2015 Strategic Priorities
-Accelerating Cash Flow & Earnings
-Adjusted EBITDA Metrics
- And much more...
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
In this NeoGenomics Laboratory Company Overview Presentation 01/09/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
NeoGenomics Company Overview highlights. It includes investment highlights, Consistent historical growth charts, accelerating cash flow & earnings, management team, testing services, customer targets, formula for success, industry dynamics, U.S. cancer market size, cancer testing market characteristics, key growth drivers...
This presentation contains statements which constitute forward-looking statements within the meaning of Section 27A of the Securities Act, as amended; Section 21E of the Securities Exchange Act of 1934; and the Private Securities Litigation Reform Act of 1995. The words “may”, “would”, “could”, “will”, “expect”, “estimate”, “anticipate”, “believe”, “intend”, “plan”, “goal”, and similar expressions and variations thereof are intended to specifically identify forward-looking statements. All statements that are not statements of historical fact are forward-looking statements.
Investors and prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. The risks that might cause such differences are identified in our filings with the Securities and Exchange Commission. We undertake no obligation to publicly update or revise the forward looking statements made in this presentation to reflect events or circumstances after
NeoGenomics Company Overview 2014-09-12 includes the following sections:
-Forward-looking Statements
-Investment Highlights
-Experienced Management Team
-Company Overview
-Proven Track Record Of Consistent Growth
-U.S. Cancer Testing Market Size $10-12 Billion
-NeoGenomics' Cancer Testing Services
-Customer Targets
-Accelerating Pace of Innovation
-90+ New Assays Launched Since January 2012
-A Growing Commercial & Facility Footprint
-Acquisition of Path Logic
-Strategic Alliance
-2014 and 2015 Strategic Priorities
-Accelerating Cash Flow & Earnings
-Adjusted EBITDA Metrics
- And much more...
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
Tech Talk by John Casey (CTO) CPLANE_NETWORKS : High Performance OpenStack Ne...nvirters
OpenStack is HOT! No doubt about it. A recent survey by The New Stack and The Linux Foundation shows OpenStack as the most popular open source project ahead of other hot projects like Docker and KVM. OpenStack is now taking its rightful place as the open source cloud solution for enterprises and service providers.
To date OpenStack networking has not yet achieved the performance, scalability and reliability that many large enterprises demand. CPLANE NETWORKS solves that problem by delivering secure multi-tenant virtual networking that overcomes the limitations of the standard Neutron networking service. By making all networking services local to the compute node and achieving near line-rate throughput, CPLANE NETWORKS Dynamic Virtual Networks (DVN) delivers mega-scale networking for the most demanding application environments.
In this session John Casey will cover the basics of DVN and explain how CPLANE NETWORKS achieves "at scale" network performance within and across data centers.
About John Casey
John Casey has over 20 years of deep technology leadership. His proven success with a variety of technical leadership roles in Telecom, Enterprise and Government and in software design and development provide the foundation for the system architecture and engineering team.
Previously John led worldwide deployment teams for both IBM’s Software Group and Narus, Inc. His work in large scale, high performance system design at Transarc Labs and Walker Interactive Systems brings leadership to the CPLANE NETWORKS product suite.
ZENITH TECHNOLOGIES provides innovative, reliable and technically advanced process measurement, automation and MES solutions to the process, pharma/biotechnology, food and electronic sectors.
Developing the right solution requires a special mix of engineering and application expertise. Our team of experienced professionals delivers tangible results right through the project lifecycle.
Biggest Automotive Brand in India, know more about us. Click to view the company profile, also this sets a basic format of a company profile should look like. More fancy coffee tables and company profiles are also uploaded to cover all genres and presentation styles. Thanks
Regards
Big Boy Toyz Team
This presentation contains statements which constitute forward-looking statements within the meaning of Section 27A of the Securities Act, as amended; Section 21E of the Securities Exchange Act of 1934; and the Private Securities Litigation Reform Act of 1995. The words “may”, “would”, “could”, “will”, “expect”, “estimate”, “anticipate”, “believe”, “intend”, “plan”, “goal”, and similar expressions and variations thereof are intended to specifically identify forward-looking statements. All statements that are not statements of historical fact are forward-looking statements.
Investors and prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. The risks that might cause such differences are identified in our filings with the Securities and Exchange Commission. We undertake no obligation to publicly update or revise the forward looking statements made in this presentation to reflect events or circumstances after the date of this presentation or to reflect the occurrence of unanticipated events.
Cancer Diagnostics Reference Laboratory / NeoGenomics April 2014 investors company overview presentation. This presentation highlights the following:
--Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hostpitals
--Strategic client partnerships created by "Tech-Only" model
--Dynamic, rapidly-growing and consolidating industry
Industry-leading revenue & test volume growth
--Strong productivity and operating leverage leading to accelerating cash flow and net income
--Strong Management Team with large cap lab experience
NeoGenomics overview presetnation ontains statements which constitute forward-looking statements within the meaning of Section 27A of the Securities Act, as amended; Section 21E of the Securities Exchange Act of 1934; and the Private Securities Litigation Reform Act of 1995. The words “may”, “would”, “could”, “will”, “expect”, “estimate”, “anticipate”, “believe”, “intend”, “plan”, “goal”, and similar expressions and variations thereof are intended to specifically identify forward-looking statements. All statements that are not statements of historical fact are forward-looking statements.
NeoGenomics Company Overview 07/24/2014. An emerging leader in fastest-growing segment of lab testing industry. They hold a robust competitive advantages and product portfolio. They have a strong management team with outstanding industry experience.
Company Overview Presentation for NeoGenomics:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
NeoGenomics Company Overview presents investment highlights. It provides details on its growing cancer genetics lab servicing oncologists, pathologists and hospitals, its strategic client partnerships, its dynamic, rapidly-growing and consolidating industry and much more…
Company Overview Presentation for November 2014.
-Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community.
-Offer the complete spectrum of diagnostic services in FISH, Flow Cytometry, Cytogenetics, digital pathology, immunohistochemistry, and molecular testing through nationwide network of laboratories
-Dedicated to providing superior service, faster TAT, and complete attention to the needs of our clients and their patients
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
Buy Verified PayPal Account | Buy Google 5 Star Reviewsusawebmarket
Buy Verified PayPal Account
Looking to buy verified PayPal accounts? Discover 7 expert tips for safely purchasing a verified PayPal account in 2024. Ensure security and reliability for your transactions.
PayPal Services Features-
🟢 Email Access
🟢 Bank Added
🟢 Card Verified
🟢 Full SSN Provided
🟢 Phone Number Access
🟢 Driving License Copy
🟢 Fasted Delivery
Client Satisfaction is Our First priority. Our services is very appropriate to buy. We assume that the first-rate way to purchase our offerings is to order on the website. If you have any worry in our cooperation usually You can order us on Skype or Telegram.
24/7 Hours Reply/Please Contact
usawebmarketEmail: support@usawebmarket.com
Skype: usawebmarket
Telegram: @usawebmarket
WhatsApp: +1(218) 203-5951
USA WEB MARKET is the Best Verified PayPal, Payoneer, Cash App, Skrill, Neteller, Stripe Account and SEO, SMM Service provider.100%Satisfection granted.100% replacement Granted.
B2B payments are rapidly changing. Find out the 5 key questions you need to be asking yourself to be sure you are mastering B2B payments today. Learn more at www.BlueSnap.com.
[Note: This is a partial preview. To download this presentation, visit:
https://www.oeconsulting.com.sg/training-presentations]
Sustainability has become an increasingly critical topic as the world recognizes the need to protect our planet and its resources for future generations. Sustainability means meeting our current needs without compromising the ability of future generations to meet theirs. It involves long-term planning and consideration of the consequences of our actions. The goal is to create strategies that ensure the long-term viability of People, Planet, and Profit.
Leading companies such as Nike, Toyota, and Siemens are prioritizing sustainable innovation in their business models, setting an example for others to follow. In this Sustainability training presentation, you will learn key concepts, principles, and practices of sustainability applicable across industries. This training aims to create awareness and educate employees, senior executives, consultants, and other key stakeholders, including investors, policymakers, and supply chain partners, on the importance and implementation of sustainability.
LEARNING OBJECTIVES
1. Develop a comprehensive understanding of the fundamental principles and concepts that form the foundation of sustainability within corporate environments.
2. Explore the sustainability implementation model, focusing on effective measures and reporting strategies to track and communicate sustainability efforts.
3. Identify and define best practices and critical success factors essential for achieving sustainability goals within organizations.
CONTENTS
1. Introduction and Key Concepts of Sustainability
2. Principles and Practices of Sustainability
3. Measures and Reporting in Sustainability
4. Sustainability Implementation & Best Practices
To download the complete presentation, visit: https://www.oeconsulting.com.sg/training-presentations
RMD24 | Debunking the non-endemic revenue myth Marvin Vacquier Droop | First ...BBPMedia1
Marvin neemt je in deze presentatie mee in de voordelen van non-endemic advertising op retail media netwerken. Hij brengt ook de uitdagingen in beeld die de markt op dit moment heeft op het gebied van retail media voor niet-leveranciers.
Retail media wordt gezien als het nieuwe advertising-medium en ook mediabureaus richten massaal retail media-afdelingen op. Merken die niet in de betreffende winkel liggen staan ook nog niet in de rij om op de retail media netwerken te adverteren. Marvin belicht de uitdagingen die er zijn om echt aansluiting te vinden op die markt van non-endemic advertising.
Improving profitability for small businessBen Wann
In this comprehensive presentation, we will explore strategies and practical tips for enhancing profitability in small businesses. Tailored to meet the unique challenges faced by small enterprises, this session covers various aspects that directly impact the bottom line. Attendees will learn how to optimize operational efficiency, manage expenses, and increase revenue through innovative marketing and customer engagement techniques.
RMD24 | Retail media: hoe zet je dit in als je geen AH of Unilever bent? Heid...BBPMedia1
Grote partijen zijn al een tijdje onderweg met retail media. Ondertussen worden in dit domein ook de kansen zichtbaar voor andere spelers in de markt. Maar met die kansen ontstaan ook vragen: Zelf retail media worden of erop adverteren? In welke fase van de funnel past het en hoe integreer je het in een mediaplan? Wat is nu precies het verschil met marketplaces en Programmatic ads? In dit half uur beslechten we de dilemma's en krijg je antwoorden op wanneer het voor jou tijd is om de volgende stap te zetten.
Enterprise Excellence is Inclusive Excellence.pdfKaiNexus
Enterprise excellence and inclusive excellence are closely linked, and real-world challenges have shown that both are essential to the success of any organization. To achieve enterprise excellence, organizations must focus on improving their operations and processes while creating an inclusive environment that engages everyone. In this interactive session, the facilitator will highlight commonly established business practices and how they limit our ability to engage everyone every day. More importantly, though, participants will likely gain increased awareness of what we can do differently to maximize enterprise excellence through deliberate inclusion.
What is Enterprise Excellence?
Enterprise Excellence is a holistic approach that's aimed at achieving world-class performance across all aspects of the organization.
What might I learn?
A way to engage all in creating Inclusive Excellence. Lessons from the US military and their parallels to the story of Harry Potter. How belt systems and CI teams can destroy inclusive practices. How leadership language invites people to the party. There are three things leaders can do to engage everyone every day: maximizing psychological safety to create environments where folks learn, contribute, and challenge the status quo.
Who might benefit? Anyone and everyone leading folks from the shop floor to top floor.
Dr. William Harvey is a seasoned Operations Leader with extensive experience in chemical processing, manufacturing, and operations management. At Michelman, he currently oversees multiple sites, leading teams in strategic planning and coaching/practicing continuous improvement. William is set to start his eighth year of teaching at the University of Cincinnati where he teaches marketing, finance, and management. William holds various certifications in change management, quality, leadership, operational excellence, team building, and DiSC, among others.
Premium MEAN Stack Development Solutions for Modern BusinessesSynapseIndia
Stay ahead of the curve with our premium MEAN Stack Development Solutions. Our expert developers utilize MongoDB, Express.js, AngularJS, and Node.js to create modern and responsive web applications. Trust us for cutting-edge solutions that drive your business growth and success.
Know more: https://www.synapseindia.com/technology/mean-stack-development-company.html
Implicitly or explicitly all competing businesses employ a strategy to select a mix
of marketing resources. Formulating such competitive strategies fundamentally
involves recognizing relationships between elements of the marketing mix (e.g.,
price and product quality), as well as assessing competitive and market conditions
(i.e., industry structure in the language of economics).
Falcon stands out as a top-tier P2P Invoice Discounting platform in India, bridging esteemed blue-chip companies and eager investors. Our goal is to transform the investment landscape in India by establishing a comprehensive destination for borrowers and investors with diverse profiles and needs, all while minimizing risk. What sets Falcon apart is the elimination of intermediaries such as commercial banks and depository institutions, allowing investors to enjoy higher yields.
NeoGenomics, Inc. Company Overview Presentation 2013_10_01
1. 1
NASDAQ: NEO
Company Overview Presentation
October 2013
Time Matters. Results Count!
“Improving Patient Care
through exceptional cancer
genetic testing services!”
2. 22
Forward-looking Statements
This presentation contains statements which constitute forward-looking
statements within the meaning of Section 27A of the Securities Act, as amended;
Section 21E of the Securities Exchange Act of 1934; and the Private Securities
Litigation Reform Act of 1995. The words “may”, “would”, “could”, “will”, “expect”,
“estimate”, “anticipate”, “believe”, “intend”, “plan”, “goal”, and similar expressions
and variations thereof are intended to specifically identify forward-looking
statements. All statements that are not statements of historical fact are forward-
looking statements.
Investors and prospective investors are cautioned that any such forward-
looking statements are not guarantees of future performance and involve risks
and uncertainties, and that actual results may differ materially from those
projected in the forward-looking statements as a result of various factors. The
risks that might cause such differences are identified in our filings with the
Securities and Exchange Commission. We undertake no obligation to publicly
update or revise the forward looking statements made in this presentation to
reflect events or circumstances after the date of this presentation or to reflect the
occurrence of unanticipated events.
3. 33
Investment Highlights
• Fast growing cancer genetics lab servicing Oncologists,
Pathologists and Hospitals
• Strategic client partnerships created by “Tech-Only” model
• Dynamic, rapidly-growing and consolidating industry
• Industry-leading revenue & test volume growth
• Strong productivity and operating leverage leading to
accelerating cash flow and net income
• Strong Management Team with large cap lab experience
5. 55
Accelerating Cash Flow & Earnings
($, 000's) 2010 2011 2012
Total Revenue 34,371$ 43,484$ 59,867$
% Growth 16.6% 26.5% 37.7%
Total Gross Margin 15,783 19,428 26,836
Gross Margin % 45.9% 44.7% 44.8%
Sales & Marketing Exp as a % of Rev 21.8% 16.0% 12.5%
Gen & Admin Exp as a % of Rev 31.2% 28.4% 26.5%
R&D Exp as a % of Rev 1.5% 1.2% 3.8%
SG&A Expenses 18,746 19,837 25,624
Total SG&A as a % of Rev 54.5% 45.6% 42.8%
Adjusted EBITDA (566)$ 2,134$ 5,997$
% Growth NA 181.0%
Net Income/(Loss) (3,303)$ (1,177)$ 65$
Diluted EPS ($0.09) ($0.03) $0.00
Summary Operating Metrics
Avg. Revenue/Test 600$ 570$ 522$
% Change -7.1% -4.9% -8.4%
6. 66
Management Team
• Douglas VanOort, Chairman & CEO
Operating Partner, Summer Street Capital Partners;
Chief Operating Officer, Quest Diagnostics
• Maher Albitar, M.D., Chief Medical Officer & Director of R&D
Med. Dir. for Hematopathology & Oncology and Chief of R&D, Quest Nichols Institute;
Director of Leukemia and Molecular Laboratory, MD Anderson Cancer Center
• Robert Gasparini, Director & Chief Scientific Officer
Director of Genetics, U.S. Labs; Worldwide Marketing Mgr., Ventana Medical Systems;
Asst. Director, Prenatal Diagnostic Center (Harvard)
• Steven Jones, Director, EVP – Finance, & Chief Compliance Officer
Chairman, Aspen Capital Group; Managing Member, Medical Venture Partners;
Vice President, Merrill Lynch Investment Banking
• George Cardoza, Chief Financial Officer
CFO, Protocol Global Solutions; Controller, Central Region, Quest Diagnostics
• Robert Horel, Vice President, Sales & Marketing
Regional Mgr., US Labs; Product Specialist, Ventana Medical Systems; Pilot, U.S. Navy
• Steven Ross, Chief Information Officer
Vice President Technology, Chico’s FAS, Inc.
7. 77
NeoGenomics’ Cancer Testing Services
Key Testing Methodologies
Cytogenetics: chromosome analysis
- “Neighborhood view of 46 houses from 1000 feet”
Flow Cytometry & IHC: cell surface marker analysis
- “Single house view from 500 feet”
Fluorescence in-situ Hybridization (FISH): gene
analysis - “Door and window view of one house”
Molecular testing: DNA/RNA analysis
-“View of serial number on door lock”
8. 88
Customer Targets
Pathologists & Hospital Pathology Groups (about 70% of Revenue)
• Enable community Pathologists to practice using sophisticated tools and tests
• Innovative technical component (TC or “tech-only”) services – Flow, FISH, IHC
• Outstanding Web-based Lab System & extensive training programs
Oncologists & Clinician Groups (about 25% of Revenue)
• Includes Hematologists, Oncologists, Dermatologists, Urologists
• Disease Panels and comprehensive molecular menus
• Increasing Opportunity to service larger practices with Tech-only model
Clinical Trials & Other (about 5% of Revenue)
• Contract research/clinical trial support work for Pharma clients
9. 99
Industry Dynamics
& Demographics
• Aging U.S. population and
prevalence of cancer
• Diagnostic testing reduces
healthcare costs and improves
clinical outcomes
• Emergence of molecular diagnostics
• Targeted therapeutics and
companion diagnostics
• Capitalize on new healthcare
paradigm
• Attract New Customers
– Promote key advantages of
“tech-only” model
– Partner with Clinician Offices
• Grow existing customer base
– Sales force productivity
– Increase share of wallet
– Promote product education
– Capitalize on competitor turmoil
• Sustainable revenue growth opportunity
• Significant degree of operating leverage in
the business model
New Products &
Solutions
Market Share Gains
• Continue to expand test menu
• Sublicensing of HDC products
– Cytogenetics/Flow/IHC systems
– Prostate/colon/pancreatic Cx Tests
– International opportunities
• Proprietary test development
• Disruptive technology for select solid
tumor cancers
• Seek new R&D partnerships
Superior Financial Model
NeoGenomics Formula for Success
10. 1010
• Molecular diagnostics transforming lab services
industry and fueling rapid growth
– Molecular diagnostics enable physicians to better
diagnose diseases and predict therapeutic efficacy
• Clinical Benefits: Effective treatment at an early stage
increases patient survival rates
• Healthcare Savings: a) forego spending on ineffective
therapies and b) effective intervention at an early stage
generally lowers overall treatment cost
– Need for companion diagnostics being driven by rising
drug costs and an increase in targeted therapeutics
• Xalkori® - Cost of ~$90,000 annually to treat non-small cell
lung cancer. 50 – 61% effective for the ~3% of the
population with certain genetic characteristics
• Diagnostic testing can significantly lower
healthcare costs and improve clinical outcomes
– Diagnostics represents only 2-3% of total healthcare
spend but influence approximately 70% - 80% of
physician decisions
• Cancer prevalence expected to increase as U.S.
population ages
– 77% of all cancers diagnosed are in people age 55 or
older, the fastest growing segment of the US
16%
17% 16%
18%
22%
25% 25% 26%
11%
13% 12% 13%
16%
19% 20% 20%
0%
5%
10%
15%
20%
25%
30%
1980 1990 2000 2010 2020 2030 2040 2050
PercentOfPopulation
Age 60 and older Age 65 and older
Current
U.S. Population Demographics
Boomer Impact on Cancer Market
Industry Dynamics
11. 1111
U.S. Cancer Testing Market Size $10-12 Billion
Hematopoietic Cancers Solid Tumor Cancers
Total Testing Market: $3 - 4 Billion $7 - 8 Billion
Est. Genetic Mkt. (TAM) ~$1 - 2 Billion ~$1 - 2 Billion
Patients in Treatment: 850,000 7.0 million
New Diagnoses/Yr.: 150,000 1.45 million
Specimen Types: Bone Marrow (350K/Yr)
Per. Blood (150K/Yr)
Lymph Nodes
Tiss. Biopsies (8-10MM)
Fine Needle Aspirates
Other Bodily Fluids
Neo Revenue Split: ~80% ~20%
12. 1212
Cancer Testing Market Characteristics
• Cancer Genetics is high growth segment of lab Industry
- ~20% annual growth in genetics testing
- ~8% annual growth in related AP testing
• Less than 400 Cancer Genetic Labs in the U.S.
- 2/3 affiliated with academic institutions
- Approximately 20% perform 80% of testing
- Only 15-20 labs with national reach
• High pace of consolidation - Recent examples include:
Target Acquiror TV/LTM Rev
Caris Diagnostics Miraca 3.5x
Genoptix Novartis 1.7x
Clarient GE Healthcare Svcs 5.8x
Genzyme Genetics LabCorp 2.5x
14. 1414
2011
4 molecular
tests
3 FISH
FL – IHC menu
2012
10-color Flow Cytometry
Implemented State-of-the-art
MolDx platform in lieu of Kits
30 new Molecular Assays
Proprietary method for increasing
sensitivity of Sanger sequencing
7 NeoTYPE MolDx Panels
New Aperio Digital Image Analysis
SVM for ALK FISH (Patent App)
Barrett’s Esoph. FISH (Patent App)
NeoARRAY/SNP Cytogenetics
Internalized 99% of send-outs
2013 (In Progress)
25-35 new Molecular tests
Add’l NeoTYPE Panels
Next Generation
Sequencing (48 genes)
ROS1 FISH
NeoSITE Melanoma FISH
Plasma/Urine-based
Prostate Test (Patent App)
SVM-based Cytogenetics
Analysis System
SVM-based Automated
FISH Analysis System v2
Accelerating Pace of Innovation
16. 1616
• Expansion of Sales Team with seasoned Professionals
• Growth of molecular assays, panels and Next Gen Sequencing
• Recent expansion in FISH and advanced flow cytometry
• New Image Analysis/Immunohistochemistry Platform
• New initiative to drive Clinical Trials
• Proprietary NeoSCORE Prostate Cancer and other proprietary tests
• M&A Opportunities
Key Growth Drivers Over the Next 3 Years
17. 1717
Productivity Increases Keeping Margins Stable
(1) Productivity calculated as the average number of lab tests completed per month per laboratory FTE.
(2) The expiration of the Medicare Technical Component (TC) Grandfather Clause took effect on 7/1/12 and resulted in an ~11% YoY Reduction in Avg Rev/Test.
47.3% 48.4%
46.1%
44.7% 44.6% 43.9% 44.5%44.8% 45.2%
47.1% 47.2%
41.5%
43.2%46.3% 45.9%
-21.8%
41.6%
-50%
-40%
-30%
-20%
-10%
0%
10%
20%
30%
40%
50%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Q409
Q110
Q210
Q310
Q410
Q111
Q211
Q311
Q411
Q112
Q212
Q312
Q412
Q113
Q213
Gross Margin % Cum Change in Avg Rev/Test(2) Cum Change in Productivity(1)